Mersana Therapeutics Inc [MRSN] stock prices are down -3.20% to $5.75 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MRSN shares have gain 41.63% over the last week, with a monthly amount glided 70.12%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results. In a post published today on Yahoo Finance, Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024.
From an analyst’s perspective:
Mersana Therapeutics Inc [NASDAQ: MRSN] stock has seen the most recent analyst activity on February 29, 2024, when Wedbush upgraded its rating to a Outperform and also boosted its price target to $7 from $2. Previously, Guggenheim upgraded its rating to Buy on February 29, 2024, and kept the price target unchanged to $7. On February 29, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $6 on the stock. Citigroup upgraded its rating to a Buy and increased its price target to $5 on December 04, 2023. Robert W. Baird downgraded its rating to a Neutral and reduced its price target to $1 on July 28, 2023. Wedbush downgraded its rating to Neutral for this stock on July 27, 2023. In a note dated July 27, 2023, Truist downgraded an Hold rating on this stock.
The stock price of Mersana Therapeutics Inc [MRSN] has been fluctuating between $0.80 and $9.62 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $5.75 at the most recent close of the market. An investor can expect a potential return of 230.43% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
The Mersana Therapeutics Inc [NASDAQ:MRSN] reported sales of 36.85M for trailing twelve months, representing a drop of -27.14%. Gross Profit Margin for this corporation currently stands at 0.94%, Pretax Profit Margin comes in at -4.66%, and Net Profit Margin reading is -4.66%. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.91.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.49 points at the first support level, and at 5.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.01, and for the 2nd resistance point, it is at 6.28.
Mersana Therapeutics Inc [MRSN] reported earnings per share of -$0.16 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.16/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.35 per share as compared to estimates of -$0.36 per share, a difference of $0.01 representing a surprise of 2.80%.
Ratios To Look Out For
It’s worth pointing out that Mersana Therapeutics Inc [NASDAQ:MRSN]’s Current Ratio is 3.36. Further, the Quick Ratio stands at 3.36, while the Cash Ratio is 2.74. Considering the valuation of this stock, the price to sales ratio is 18.93, the price to book ratio is 18.81.
Transactions by insiders
Recent insider trading involved Protopapas Anna, Director, that happened on Jan 16 when 29399.0 shares were sold. SVP, Chief Sci.&Tech. Officer, Lowinger Timothy B completed a deal on Jan 16 to sell 10409.0 shares. Meanwhile, SVP, COO & CFO DeSchuytner Brian sold 9327.0 shares on Jan 16.
